In a recent study, researchers compared the efficacy of several epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of certain types of non-small cell lung cancer. READ MORE
The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer.
Long-term data from a recent trial suggest that continuation of treatment with first-generation EGFR TKIs beyond EGFR-positive NSCLC progression does not improve overall survival.
The American Society of Clinical Oncology has updated their guideline on systemic therapy for non-small cell lung cancer for the first time since 2015.
Research in Review
Patients with advanced non-small cell lung cancer who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy.
Adjuvant treatment with the targeted therapy gefitinib significantly improved disease-free survival over standard of care after surgery for patients with non–small cell lung cancer, according to research that will be presented at the 2017 ASCO Annual Meeting.
Selecting patients with cyclooxygenase-2 expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer.
Patients with ALK-rearranged non-small cell lung cancer who are treated with crizotinib may experience increased progression-free survival with a decrease in a type of circulating tumor cells.